Comparison of the efficacy and safety of topical minoxidil and topical alfatradiol in the treatment of androgenetic alopecia in women.
BACKGROUND
Two drugs which are approved for the treatment of androgenetic alopecia in women in Germany were compared with regard to their influence on hair growth.


METHODS
Patients were randomized to group I (n = 52) who used 2% minoxidil solution twice daily for a period of 12 months or to group II (n = 51) who used 0.025% alfatradiol solution once daily for 6 months and were then switched to 2% minoxidil solution for months 7-12. Changes in hair growth parameters were determined using the TrichoScan.


RESULTS
Topical treatment with 2% minoxidil solution for 6 months resulted in a significant increase of cumulative hair thickness (p < 0.0001) and absolute hair density (p < or = 0.0025), whereas these parameters of hair growth remained nearly unchanged after 6 months of treatment with alfatradiol solution. Evaluation of the same parameters from month 7 to month 12 demonstrated that 12 months minoxidil treatment resulted in an increasing stabilization (group I). After the alfatradiol-->minoxidil switch in group II a significant increase in cumulative hair thickness (p < 0.0001) and absolute hair density (p < 0.0001) was achieved. Both study medications were well tolerated.


CONCLUSIONS
Treatment with minoxidil can induce an increase in hair density and hair thickness,whereas treatment with alfatradiol results in deceleration or stabilization of hair loss.
Blume-Peytavi
Ulrike
U
Department of Dermatology and Allergy, Charité- Medical University, Berlin, Germany. ulrike.blume-peytavi@charite.de
Kunte
Christian
C
Krisp
Andreas
A
Garcia Bartels
Natalie
N
Ellwanger
Ulf
U
Hoffmann
Rolf
R
D000287:Administration, Topical; D000505:Alopecia / Q000188:drug therapy*; D003875:Drug Eruptions / Q000209:etiology; D004958:Estradiol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D005260:Female; D005858:Germany; D006197:Hair / Q000187:drug effects* / Q000254:growth & development*; D006801:Humans; D008875:Middle Aged; D008914:Minoxidil / Q000008:administration & dosage* / Q000009:adverse effects; D012536:Scalp Dermatoses / Q000139:chemically induced; D016896:Treatment Outcome; D016387:Women's Health
C519808:alfatradiol; D004958:Estradiol; D008914:Minoxidil